Menopause
medical conditions

Menopause

Explore the available health information, treatment context, and integrative evidence for Menopause.

Background
  • Menopause is when a woman's menstrual periods stop completely. It signals the end of the ovaries releasing eggs for fertilization. A woman is said to have gone through menopause when her menses have stopped for an entire year. Menopause generally occurs between the ages of 45-55, although it can occur as early as the 30s or as late as the 60s. It can also result from the surgical removal of both ovaries. A woman can still get pregnant during menopause until she has gone at least 12 months without menstruating (a period).
  • Changes and symptoms include: a change in menstruation (periods may be shorter or longer, lighter or heavier, with more or less time in between); hot flashes and/or night sweats; trouble sleeping; vaginal dryness; mood swings; trouble focusing; and, less commonly, hair loss on the head but increased hair on the face. About 85% of women experiencing menopause will have hot flashes.
  • All women will experience menopause. Menopause is not considered a disorder and most women do not need treatment for it. However, if symptoms are severe, medications may be used to help alleviate symptoms.
  • Researchers have estimated that more than 1.3 million women in the United States and 25 million women worldwide experience menopause annually. There are about 470 million postmenopausal women worldwide, a number that is expected to increase to 1.2 billion by the year 2030.
  • Some women take hormone replacement therapy (HRT) to relieve the symptoms associated with menopause. HRT is medication containing one or more female hormones, commonly estrogen plus progestin (synthetic progesterone). HRT may also protect against osteoporosis. However, HRT also has risks. It can increase the risk of breast cancer, heart disease, and stroke. Certain types of HRT have a higher risk, and each woman's own risks can vary depending upon her health history and lifestyle.
  • Perimenopause: During perimenopause, the woman may begin to experience menopausal physical and emotional signs and symptoms, such as hot flashes and depression, even though they still menstruate. The average length of perimenopause is four years, but for some women this stage may last only a few months or continue for 10 years. Perimenopause ends the first year after menopause, when a woman has gone 12 months without having her period. Periods (menstruation) tend to be irregular during this time and may be shorter or longer or even absent.
  • Despite a decline in fertility during the perimenopause stage, individuals can still become pregnant. If the individual does not want to become pregnant, they should continue to use some form of birth control until menopause is reached.
  • Postmenopause: Postmenopause is a time when most of the distress of the menopausal changes have faded. Hot flashes may seem milder or less frequent and energy, emotional, and hormonal levels may seem to have stabilized. During postmenopause, women are at a higher risk for developing osteoporosis (bone loss) and heart disease, due to the decrease in circulating estrogen. The postmenopausal phase begins when 12 full months have passed since the last menstrual period.
Signs and Symptoms
  • Menstrual changes: Many women experience irregular periods due to the changing hormone levels and the decreased frequency of ovulation (egg release). The changes may be subtle at first and then gradually become more noticeable. Common changes include short cycles (less than 28 days), bleeding for fewer days than usual, heavier than usual bleeding, lighter than usual bleeding, and missed periods.
  • Although menstrual irregularities are expected during menopause, menstrual changes can also be caused by conditions such as fibroids or pregnancy. Women who experience heavy bleeding (usually with clots), periods that come more often than every three weeks, spotting between periods, or bleeding after intercourse, should see their doctor or other healthcare provider.
  • After menopause, women no longer menstruate. Any woman who experiences vaginal bleeding after menopause should see her doctor or other healthcare provider. Hormone treatments can sometimes cause vaginal bleeding to resume.
  • Changes in the body during menopause are called climacteric symptoms. They include hot flashes, skin and hair changes, and vaginal changes.
  • Hot flashes: As many as 85% of women experience hot flashes during menopause. Hot flashes are vasomotor symptoms that cause a warm or hot flushed sensation that usually begins in the head and face and then radiates down the neck to other parts of the body. There may be red blotches on the skin. Each hot flash averages 2.7 minutes and is characterized by a sudden increase in heart rate, an increase in peripheral blood flow, which leads to a rise in skin temperature, and a sudden onset of sweating, particularly on the upper body. Hot flashes can occur before, during, or after menopause. Hot flashes can begin when a woman's cycles are still regular or, more commonly, as menopause approaches and her cycles become irregular. They usually last for less than a year following the last menstrual period, although some women continue to experience hot flashes five to ten years after menopause. Hot flashes can occur once a month, once a week, or several times an hour. They can happen any time of day or night. If they happen at night (such as night sweats), they can interrupt sleep and drench clothing and sheets. Loss of sleep can eventually lead to irritability and fatigue.
  • Skin and hair changes: The process of aging can cause many changes in the body that result in skin and hair changes. Estrogen helps keeps the skin smooth and moist. The loss of estrogen during menopause makes the skin dry, thin, lax, and transparent. The blood vessels are easier to see, and the skin bruises easily. The woman may experience growth of facial hair, but thinning of hair in the temple region.
  • Vaginal changes: Women may experience vaginal changes. In particular, the tissues of the vagina and vulva may become thin and dry (called vaginal atrophy), which can lead to itching and discomfort during sexual intercourse. In some women, vaginal dryness is the first sign of menopause.
  • Other changes: Other changes that may occur during menopause includes: loss of bladder tone resulting in stress incontinence (leaking urine when coughing, sneezing, laughing, or exercise); headaches; dizziness; loss of some muscle strength and tone; increasing loss of bones, increasing the risk for osteoporosis; increasing risk for a heart attack when estrogen levels drop (however, the addition of estrogen as a prescribed medication after menopause can lead to an increase in heart attack and stroke); emotional changes associated with menopause such as irritability, mood changes, lack of concentration, difficulty with memory, tension, anxiety, and depression; and insomnia that may result from hot flashes that interrupt sleep.
Diagnosis
  • A doctor will review the woman's medical history and perform a physical examination, including a pelvic exam. During the pelvic exam, a doctor will check for any abnormalities in the reproductive organs and look for indications of infection. There are no unique physical findings or laboratory tests to positively diagnose menopause.
  • The signs and symptoms of menopause, such as hot flashes and mood swings, are enough to tell most women they have begun going through the transition. Under certain circumstances, a doctor may check the level of follicle-stimulating hormone (FSH) and estrogen (estradiol) with a blood test. As menopause occurs, FSH levels increase and estradiol levels decrease. A doctor may also recommend a blood test to determine the level of thyroid-stimulating hormone, as hypothyroidism (low thyroid hormone levels) can cause symptoms similar to those of menopause, such as swelling, mood changes, and hot flashes.
  • The medical history and physical examination involve an evaluation of the symptoms and when they occur in relation to menstruation. Many healthcare providers advise women to keep a diary of menstrual cycles and the physical and psychological changes they experience over the course of several months. The menstrual diary provides clues to the physician and helps women understand and cope with the changes.
Complications
  • Several chronic medical conditions tend to appear after menopause. By becoming aware of the following conditions, women can take steps to help reduce their risk.
  • Cardiovascular disease: When estrogen levels decline, the risk of cardiovascular disease increases. Heart disease is the leading cause of death in women as well as in men. Risk-reduction steps for developing heart disease include stopping smoking, reducing high blood pressure, getting regular aerobic exercise, and eating a diet low in saturated fats and plentiful in whole grains, fruits, and vegetables.
  • Osteoporosis: During the first few years after menopause, women may lose bone density at a rapid rate, increasing their risk of osteoporosis. Osteoporosis is a condition that causes bones to become brittle and weak, leading to an increased risk of fractures. Postmenopausal women are especially susceptible to fractures of the hip, wrist, and spine. It is important for all women to get adequate calcium and vitamin D. It is recommended by healthcare professionals for postmenopausal women to have about 1,200-1,500 milligrams of elemental calcium and 800 I.U. (international units) of vitamin D daily. Healthcare professionals recommend regular exercise. Strength training and weight-bearing activities such as walking and jogging are especially beneficial in keeping the bones strong and healthy. It is important to check for the amount of elemental calcium on the supplement label.
  • Urinary incontinence: Urinary incontinence is the loss of bladder control. As the tissues of the vagina and urethra lose their elasticity, postmenopausal women may experience a frequent, sudden, strong urge to urinate, followed by an involuntary loss of urine (urge incontinence), or the loss of urine with coughing, laughing, or lifting (stress incontinence).
  • Weight gain: Many women gain weight during the menopausal transition. Individuals may need to eat less, perhaps as many as 200-400 fewer calories a day, and exercise more just to maintain their current weight.
Treatment
  • Calcium management: Adequate calcium intake is important to prevent osteoporosis and bone fractures. Daily elemental calcium intake for postmenopausal women should be around 1,200 milligrams. Women should eat foods rich in calcium (such as dairy products, leafy green vegetables, tofu, calcium-fortified foods), as well as foods that promote calcium absorption. A glass of milk provides about 300 milligrams of calcium. Intake of foods that rob the bones of calcium, such as animal protein and salt, should be limited. Vitamin D helps the body absorb calcium. Fifteen minutes of sun exposure every day provides sufficient vitamin D. Foods such as fortified milk, liver, and tuna contain vitamin D. Women should ask their healthcare provider or nutritionist if they should take a vitamin D supplement.
  • Calcium supplements are available in several forms: amino acid chelate, calcium carbonate, calcium chloride, calcium lactate, calcium gluconate, bone meal, dolomite, hydroxyappetite, and calcium citrate. To maximize absorption, supplements containing amino acid chelate, calcium citrate, gluconate, or hydroxyappetite should be taken. Make sure to look for elemental calcium amounts on the label.
  • Exercise: Exercise is an important part of preventative healthcare for postmenopausal women. By increasing cardiovascular fitness and strengthening the bones, exercise helps prevent heart disease and osteoporosis. Low impact, weight-bearing exercises, such as walking, jogging, tennis, racquetball, and dancing, are helpful. Women diagnosed with osteoporosis or cardiovascular disease should consult with their healthcare provider before initiating an exercise program.
  • Hormone replacement therapy: Hormone replacement therapy (HRT) uses estrogens and progestin (synthetic progesterone) to ease the symptoms of menopause. The hormones are available in a variety of forms: pills, vaginal creams, vaginal ring inserts, implants, injections, and patches worn on the skin.
  • HRT has many short-term and long-term side effects. It is important to weigh all of the potential benefits and risks, preferences, and needs before beginning HRT. The benefits and side effects vary considerably from woman to woman. Women who take HRT should be closely monitored by a healthcare professional to ensure that they benefit as much as possible from the hormone therapy. Sometimes, changing the dosage or the way it is administered can help to control side effects.
  • Minor side effects include bloating, breast tenderness, cramping, irritability, depression, and menstrual bleeding for months or years following menopause. More serious risks include: breast cancer - women who have not had a hysterectomy and use estrogen supplements are at increased risk for invasive breast cancer and cardiovascular disease - HRT causes an increased risk for stroke (neurological damage caused by a lack of oxygen to the brain), heart attack, and cardiovascular disease.
  • Endometrial cancer has been linked to high-dose estrogen supplements. Women who have not had their uterus removed are prescribed low doses of estrogen with progestin (progestin protects against endometrial cancer).
  • Women who take HRT are at increased risk for deep vein thrombosis (DVT or blood clots).
  • HRT may help to prevent or delay the development of many diseases, including: osteoporosis; Alzheimer's disease; colon cancer; macular degeneration - the leading cause of visual impairment in persons over age 50; urinary incontinence; and skin aging.
  • Various types and dosages of estrogen and progestin are available and the type of HRT often depends on particular symptoms. For example, women who experience vaginal dryness may opt for a vaginal cream or vaginal ring insert, both of which alleviate dryness. The vaginal ring insert can also help urinary tract problems. For women who suffer from hot flashes, pills or patches may be helpful.
  • Due to the potential health risks involved with taking HRT, doctors will prescribe the lowest possible dosage for the shortest period of time when treating symptoms of menopause. Topical application of progesterone is commonly used as an alternative to HRT, especially if vaginal dryness is present.
  • Hormonal medications :
  • Estrogen therapy remains, by far, the most effective treatment option for relieving menopausal hot flashes. Depending on the individual's personal and family medical history, a doctor may recommend estrogen in the lowest dose needed to provide symptom relief for the individual.
  • Conjugated estrogens: Conjugated estrogens are a mixture of estrogens prescribed to treat menopausal symptoms. The conjugated estrogens in Premarin® and Premarin Vaginal Cream® are obtained from pregnant mare urine. The conjugated estrogens in Cenestin® are synthetic.
  • Dienestrol: Dienestrol (Ortho-Dienestrol®) is a synthetic, nonsteroidal, estrogen vaginal cream used to treat atrophic vaginitis. Side effects include vaginal discharge, increased vaginal discomfort, uterine bleeding, vaginal burning sensation, breast tenderness, and peripheral edema.
  • Esterified estrogens: Esterified estrogens (Estratab®, Menest®) are estrogenic substances consisting of 75-85% natural estrogens and 15-25% equine (mare urine) estrogens. They are supplied in tablet form and are used to treat hot flashes and atrophic vaginitis and urethritis (infections due to thinning and drying of vaginal tissues).
  • Estradiol: Estradiol is one of the three major estrogens made by the human body and is the major estrogen secreted during the menstrual years. It is available as an oral pill (Estrace®), transdermal skin patch (Climara®, Estraderm®, Vivelle®), vaginal tablet (Vagifem®), and vaginal cream (Estrace Vaginal Cream®).
  • Estropipate (estrone): Estropipate is an estrogenic substance derived from estrone, one of the three major estrogens produced by the body. Estrone is produced from estradiol and is a less potent estrogen. It is available in pill form (Ogen®, Ortho-Est®) and prescribed to treat hot flashes and vaginal atrophy and to help prevent osteoporosis.
  • Ethinyl estradiol: Ethinyl estradiol (Estinyl®) is a synthetic nonsteroidal estrogen available as a tablet that is prescribed to treat hot flashes (vasomotor symptom). It is administered on a cyclical basis (such as three weeks on and one week off) with attempts to discontinue or taper at three to six month intervals.
  • Testosterone: Testosterone is one of the androgens or male hormones and is also produced by women. Testosterone contributes to muscle strength, appetite, well-being, and sex drive (libido). The level of testosterone falls rapidly after menopause, and some women take testosterone supplements in addition to estrogen and progestin as part of HRT. However, supplemental testosterone can produce side effects and has potentially serious risks. Common side effects include weight gain, acne, facial hair, and liver disease. Testosterone can exacerbate estrogen's carcinogenic effect on breast and uterine tissue.
  • Other medications :
  • Low-dose antidepressants: Venlafaxine (Effexor®) is an antidepressant in a group of drugs called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs). Effexor® has been reported to decrease menopausal hot flashes. SSRIs may be helpful, including fluoxetine (Prozac®, Sarafem®), paroxetine (Paxil®), citalopram (Celexa®), and sertraline (Zoloft®). Side effects include drowsiness and fatigue.
  • Gabapentin (Neurontin®): Gabapentin (Neurontin®) is commonly used to treat seizures and for neuropathy (nerve pain), but it also has been reported to significantly reduce hot flashes. Side effects include drowsiness, sedation, blurred vision, nausea, vomiting, or tremor.
  • Clonidine (Catapres®): Clonidine (Catapres®) is typically used to treat high blood pressure. However clonidine may significantly reduce the frequency of hot flashes. Side effects include slow heart rate, low blood pressure, fatigue, dizziness, headache, constipation, nausea, vomiting, diarrhea, insomnia, or a dry mouth.
  • Bisphosphonates: Alendronate (Fosamax®), risedronate (Actonel®), ibandronate (Boniva®), and zoledronate (Zometa®) are approved by the U.S. Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women. Alendronate is also approved for management of osteoporosis in men. Both alendronate and risedronate are approved for the prevention and treatment of steroid-induced osteoporosis in men and women. Bisphosphonates help slow down bone loss and have been shown to decrease the risk of fractures. All are taken on an empty stomach with water. Because bisphosphonates have the potential for irritating the esophagus, remaining upright for at least an hour after taking these medications is recommended by healthcare professionals. Alendronate and risedronate can be taken once a week, while ibandronate can be taken once a month. An IV form of ibandronate, given through the vein every three months, also has been FDA-approved for the management of osteoporosis. Another IV bisphosphonate being studied for osteoporosis is zoledronic acid or zoledronate (Zometa®). This form is injected once yearly.
  • Side effects, which can be severe, include nausea, abdominal pain, and the risk of an inflamed esophagus or esophageal ulcers, especially if the individual has had acid reflux or ulcers in the past. If individuals cannot tolerate oral bisphosphonates, the doctor may recommend the periodic intravenous infusions of a bisphosphonate.
  • Use of bisphosphonates in women who are pregnant or breastfeeding is not well studied. Blood calcium levels in women who take bisphosphonates during pregnancy are usually monitored. Individuals using ibandronate injection will have blood levels of creatinine measured prior to each dose to determine kidney function. Creatinine is measured using blood tests.
  • Selective estrogen receptor modulators (SERMs): Selective estrogen receptor modulators (SERMS) mimic the positive effects of estrogen on bones without some of the serious side effects such as breast cancer and stroke. Raloxifene (Evista®) decreases spine fractures in women, and is approved for use only in women at this time. Hot flashes are a common side effect of raloxifene, and individuals with a history of blood clots should not use this drug.
  • Vaginal estrogen: To relieve vaginal dryness, estrogen can be administered locally in the vagina using a vaginal tablet (Vagifem®), ring (Nuvaring®), or cream (Premarin® vaginal cream). This treatment releases just a small amount of estrogen, which is absorbed by the vaginal tissue. It can help relieve vaginal dryness, discomfort with intercourse, and some urinary symptoms.
References

Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.

  • American College of Obstetricians and Gynecologists. . Accessed April 15, 2009.
  • Bruno D, Feeney KJ. Management of postmenopausal symptoms in breast cancer survivors. Semin Oncol. 2006;33(6):696-707. View Abstract
  • Centers for Disease Control and Prevention. . Accessed April 15, 2009.
  • Douglas S. Premenstrual syndrome. Evidence-based treatment in family practice. Can Fam Physician. 2002 Nov;48:1789-97. View Abstract
  • Harman SM. Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend Med. 2006;3(4):254-69. View Abstract
  • Lata PF, Elliott ME. Patient assessment in the diagnosis, prevention, and treatment of osteoporosis. Nutr Clin Pract. 2007;22(3):261-75. View Abstract
  • Middleton ET, Steel SA. The effects of short-term hormone replacement therapy on long-term bone mineral density. Climacteric. 2007;10(3):257-63. View Abstract
  • National Women's Health Center. . Accessed April 15, 2009.
  • Natural Standard: The Authority on Integrative Medicine. . Copyright © 2009. Accessed April 15, 2009.
  • North American Menopause Society. . Accessed April 15, 2009.
  • Rosano GM, Vitale C, Marazzi G, et al. Menopause and cardiovascular disease: the evidence. Climacteric. 2007;10 Suppl 1:19-24. View Abstract
  • Women's Health America. . Accessed April 15, 2009.